ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Alectinib is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 2:43 AM UTC“Against durvalumab after chemoradiotherapy, ALK-positive stage III”
  • The role rule says the same.
  • So Alectinib's page lists this study under “Testing it”.
4 links0 made here, not in the record8 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05170204A Study Evaluating theEfficacy and Safety ofMultiple Therapies inCohorts of ParticipantsWith Locally Advanced,Unresectable, Stage IIINon-Small Cell Lung CancerHoffmann-La RochePhase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Version of 2026-11-02CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSAlectinibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEntrectinibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDurvalumabIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 2 · changes seen, not judgments
Nov 3AlectinibClaude Opus 5.5TestedCurrent
Nov 3EntrectinibClaude Opus 5.5TestedCurrent
Nov 3DurvalumabClaude Opus 5.5ComparatorCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 18AlectinibRule based · role ruleTestedAgrees
Nov 18EntrectinibRule based · role ruleTestedAgrees
Nov 18DurvalumabRule based · role ruleComparatorAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.